Concurrent and sequential administration of interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF) for immune activation following high dose chemotherapy (HDC) and autologous stem cell transplant (ASCT).

被引：0

|

作者：

Bachier, C

Teale, J

Lanzkron, S

Hougham, M

Nanez, A

Huerta, J

Childs, C

LeMaistre, CF

机构：

[1] S Texas Canc Inst, San Antonio, TX USA

[2] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA

来源：

BLOOD | 1998年 / 92卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4550

引用

收藏

页码：360B / 360B

页数：1

相关论文

共 50 条

[1] Interleukin 2 (IL-2) and granulocyte-macrophage colony stimulating factor (sargramostin) (GM-CSF) following autologous peripheral blood stem cell transplant (ASCT) for breast cancer
Holmberg, LA
Bensinger, W
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 98 - 99
[2] Interleukin-2 (IL-2) and granulocyte-macrophage stimulating factor (GM-CSF) for treatment of relapse after allogeneic stem cell transplant (ASCT)
Bachier, CR
Shaughnessy, P
Wall, D
Grimley, M
LeMaistre, CF
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 56 - 56
[3] GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) INCREASES IL-2 BINDING ON HUMAN NEUTROPHILS
GIRARD, D
HEITZ, D
GOSSELIN, J
BEAULIEU, A
CLINICAL RESEARCH, 1994, 42 (03): : A460 - A460
[4] In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma
Hasskamp, Joanne H.
Elias, E. George
Zapas, John L.
JOURNAL OF CLINICAL IMMUNOLOGY, 2006, 26 (04) : 331 - 338
[5] In Vivo Effects of Sequential Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Interleukin-2 (IL-2) on Circulating Dendritic Cells (DC) in Patients with Surgically Resected High Risk Cutaneous Melanoma
JOANNE H. HASSKAMP
E. GEORGE ELIAS
JOHN L. ZAPAS
Journal of Clinical Immunology, 2006, 26 : 331 - 338
[6] Lymphodepletion with high-dose interleukin-2 (IL-2) and granulocyte macrophage-colony stimulating factor (GM-CSF) in metastatic melanoma patients: An interim analysis.
Ketchum, S. L.
Cole, B.
Margolin, K.
McDermott, D.
Crocenzi, T.
Roberts, J.
Crosby, N.
Meehan, K.
Fisher, J.
Ernstoff, M. S.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 461S - 461S
[7] Comparative effects of three cytokine regimens after high-dose cyclophosphamide: Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF
Ballestrero, A
Ferrando, F
Garuti, A
Basta, P
Gonella, R
Stura, P
Mela, GS
Sessarego, M
Gobbi, M
Patrone, F
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1296 - 1303
[8] The effects of systemic granulocyte-macrophage colony stimulating factor (GM-CSF) and Interleukin-2 (IL-2) on peripheral blood dendritic cell (DC) counts in patients with stage IIB-IVmelanoma.
Zapas, JL
Hasskamp, JH
Beam, SL
Brown, SD
Jablonski, KA
Elias, EG
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 190S - 190S
[9] Engraftment syndrome after autologous hematopoietic stem cell transplant supported by granulocyte-colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor (GM-CSF)
M Akasheh
D Eastwood
D H Vesole
Bone Marrow Transplantation, 2003, 31 : 113 - 116
[10] Maintenance therapy with subcutaneous (SC) low dose recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) for breast cancer patients following autologous stem cell transplantation (ASCT).
Nagler, A
Ackerstein, A
Or, R
Varadi, G
Slavin, S
BLOOD, 1999, 94 (10) : 379B - 379B

← 1 2 3 4 5 →